SEC Form 4 · accession 0001144204-17-021128
PLx Pharma Inc. · PLXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry Kagan
Director
Period of report
Jan 17, 2017
Accepted (ET)
Apr 20, 2017 · 6:26 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001497504
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF1 | $1.80 | Jan 17, 2017 | A | 20,000 | A | — | Jan 17, 2027 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Options to purchase shares of common stock vest as follows: options to purchase 10,000 shares of common stock vested on January 17, 2017; options to purchase 416 shares of common stock vest monthly in each of the 23 months after the date of grant and options to purchase 432 shares of common stock will vest on the 24th month anniversary of the date of grant.
Remarks
The reporting person resigned as a member of the Board of Directors of Dipexium Pharmaceuticals, Inc. effective April 19, 2017. As a result, the reporting person is no longer subject to Section 16 in connection with his transactions in the equity securities of Dipexium Pharmaceuticals, Inc. and therefore will no longer report any such transactions on Form 4 or Form 5.